Skip to main content

Table 2 Quantitative and qualitative computed tomography (CT) findings related to COVID-19, and secondary CT findings

From: Evaluation of novel coronavirus disease (COVID-19) using quantitative lung CT and clinical data: prediction of short-term outcome

Volume of disease (cm3; median, range) 249.5 (9.9–1505)
Uni/bilateral
 Unilateral 7/106 (6.6%)
 Bilateral 99/106 (93.4%)
Affected lobes
 Only lower lobe(s) 5/106 (4.7%)
 Lower lobe(s) + at least one other lobe 97/106 (91.5%)
 No lower lobe involvement 4/106 (3.8%)
Gradient
 Apicobasal gradient 49/106 (46.2%)
 No apicobasal gradient 57/106 (53.8%)
Distribution
 Peripheral 39/106 (36.8%)
 Central 2/106 (1.9%)
 Mixed 65/106 (61.3%)
CT pattern
 Pure GGO 11/106 (10.4%)
 GGO + septal thickening 46/106 (43.4%)
 GGO + consolidation 49/106 (46.2%)
Predominant type
 GGO 79/106 (74.5%)
 Consolidation 27/106 (25.5%)
CT sign
 Reverse halo 7/106 (6.6%)
 Linear opacities 66/106 (62.3%)
 Nodules 28/106 (26.4%)
Secondary findings
 Emphysema 13/106 (12.3%)
 Fibrosis 8/106 (7.5%)
 Enlarged lymph nodes (≥ 10 mm short axis) 33/106 (31.1%)
 Pleural effusion 10/106 (9.4%)
 Pleural thickening 15/106 (14.15%)
 Aortic Calcification 45/106 (42.5%)
 Coronary calcification 53/106 (50.0%)
Other
 Pneumomediastinum 1/106 (0.9%)
 Iatrogenic pneumothorax and subcutaneous emphysema 1/106 (0.9%)
  1. GGO Ground-glass opacities